Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single‐center experience
- 11 February 2020
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 24 (4) , e13664
Abstract
Background/objectives: Despite the apparent efficacy and favorable toxicity profile of TKIs, allogeneic SCT remains the only curative treatment for CML especially in younger patients, but TRM should be considered. We evaluated the clinical outcomes of pediatric CML patients who had SCT in our center.Methods: This retrospective study included children with CML, who received an allogeneic SCT at Children Cancer Hospital Egypt, 57357, from 2007 to 2017. All patients received myeloablative conditioning chemotherapy containing busulfan/cyclophosphamide followed by stem cell infusion from MRD.Results: From 121 patients diagnosed with CML, 43 had available MRD and subjected to HSCT while 78 patients continued TKI therapy. The median time to transplant from diagnosis was 13 months. At initial diagnosis, there were 39 patients in CP and 4 had blastic crises. Bone marrow harvest was the stem cell source in 32 patients, while 11 cases received mobilized peripheral blood stem cells with average stem cell dose of 4.45 × 106/kg. The probabilities of overall survival and event‐free survival at 5 years were 97.4% and 79.8%, respectively. TRM at 100 days and TRM at 1‐year post‐transplant were 0%. The incidence of chronic GVHD was significantly higher in peripheral blood than bone marrow stem cell source (P = .004).Conclusion: Considering the excellent survival rates and very low TRM, HSCT is still a valid option for pediatric patients with newly diagnosed CML with best using marrow stem cell source to avoid a significant risk of cGVHD and its related complications.Keywords
This publication has 30 references indexed in Scilit:
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyCancer, 2012
- Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975‐1999Cancer, 2008
- Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year periodBritish Journal of Haematology, 2005
- P210 and P190 Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family MembersJournal of Biological Chemistry, 1996
- Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.Journal of Experimental Medicine, 1996
- The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.Proceedings of the National Academy of Sciences, 1995
- Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cellsBlood, 1993
- Dominant negative MYC blocks transformation by ABL oncogenesCell, 1992
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973